期刊文献+

小鼠注射新型重组人肿瘤坏死因子的药代动力学 被引量:4

Pharmacokinetic study of new recombinant human tumor necrosis factor (nrhTNF α) in mice
下载PDF
导出
摘要 目的 研究新型重组人肿瘤坏死因子 (nrh TNFα)在小鼠体内的药代动力学 .方法 给小鼠按 10 ,2 0和 40μg·kg- 1 剂量 im nrh TNFα后 ,不同时间点采血 ,分离血清 ,采用高效液相色谱法 (HPL C)分离结合同位素法和酶联免疫法(EL ISA)测定血清中 nrh TNFα的浓度 .结果 小鼠 im后 ,nrh TNFα能迅速进入血液循环 ,约在 0 .5 h内达到最大血浓度 ,未降解的 nrh TNFα在体内的分布以肾脏最高 ,血液次之 ,其后为肺、肝 ,脑浓度最低 .消除半衰期 (T1 /2 )在 0 .6~ 1h.两种方法所得 Cmax和 AUC与剂量呈显著相关 .与 iv比较 ,im给药 nrh TNFα的绝对生物利用度仅为 0 .16 6 ,表明nrh TNFα在体内易代谢消除 .结论 阐明了 nrh AIM To study the pharmacokinetics of nrhTNF α in mice. METHODS Both methods of HPLC RA (Measuring the radioactivity of 125 I nrhTNF α after sample separated with HPLC) and Enzyme linked immunosorbent assay (ELISA) were used to detect nrhTNF α in serum. RESULTS nrhTNF α entered into circulation rapidly after im injection to mice at doses of 10, 20 and 40 μg·kg -1 . The time to reach maximum serum concentration of nrhTNF α was 0.5 h. The levels of undegraded nrhTNF α in kidney ranked first, blood second, lung third, liver fouth, and brain last. The half life ( T 1/2 ) of nrhTNF α was in 0.6~1 h. The Cmax and AUC were correlated with dosage for both methods. Comparing with iv injection, the absolute bioavailability after im injection was 0.166, indicating that nrhTNF α was easy to be metabolized and eliminated in the body. CONCLUSION The above results demonstrate the pharmacokinetics of undegraded nrhTNF α in mice.
出处 《第四军医大学学报》 北大核心 2002年第3期216-219,共4页 Journal of the Fourth Military Medical University
基金 全军"八五"科技攻关课题 ( 91C0 41-0 15 6 )
关键词 肿瘤坏死因子Α 药代动力学 高效液相色谱法 酶联免疫法 小鼠 tumor necrosis factor α pharmacokinetics HPLC ELISA mice
  • 相关文献

参考文献5

二级参考文献26

  • 1金伯泉,刘雪松.转化生长因子-β对免疫系统的调节作用[J].免疫学杂志,1989,5(4):265-268. 被引量:2
  • 2刘玮,陆裕朴.异种植骨抗原性的免疫组织化学实验研究[J].中华骨科杂志,1989,9(1):53-54. 被引量:30
  • 3戴克戎.骨溶解与人工关节后期松动[J].中华骨科杂志,1997,17(1):3-4. 被引量:66
  • 4[1] Espersen GT, Mathiesen O, Grunnet N, Jensen S et al. Cytokine plasma levels and lymphocyte subsets in patient withnewly diagnosed insulin-dependent (type 1)diabetes mellitus before and following initial insulin treatment[J]. APMIS, 1997; 101(6):703-706.
  • 5[2] Thomas MP, Hemming P, Jens M et al. Monokine antagonism is reduced in patients with IDDM[J]. Diabetes, 1994; 43(10):1242-1247.
  • 6[3] Molvig, Bak L,Christensen P et al. Endotoxin-stimulated human monocyte secretion of interleukin-1, tumur necrosis factor alpha, and prostaglandin E2 shows stable interindividual difference[J]. Scand J Immunol, 1988; 27(6):705-716.
  • 7[4] Harrsion LC, Honeyman MC, De Aizpurua HJ et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subject at risk of insulin-dependent diabetes[J]. Lancet, 1993; 341(5):1365-1369.
  • 8[5] Foulis AK, McGill M,Farquharson MA. Insulitis in type 1 (insulin-γ dependent)diabetes mellitus in man: Macrophages,lymphocytes,and interferon-γ containing cells[J]. J Pathol, 1991;165(2):97-103.
  • 9[6] Kroemer G, Wick G. The role of interleukin-2 in autoimmunity [J]. Immunol Today, 1989; 10(2):245-251.
  • 10[7] Kolb H, Zielasek J, Treichel U et al. Recombinant interleukin-2 enchanced spontaneous diabetes in BB rat[J]. Eur J Immunol, 1986; 16(2):209-212.

共引文献45

同被引文献19

  • 1易先金,金一尊,丁立,倪逴,王文吉.MTT法研究三种放射增敏剂对视网膜母细胞瘤的毒性作用[J].上海医科大学学报,1994,21(5):347-350. 被引量:3
  • 2Nakamoto T, Inagawa H, Takagi K, et al. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumor[J]. Anticancer Res, 2000,20(6A): 4087.
  • 3Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti - tumor effect of actinomycin D by tumor necrosis factor alpha in mice:.correlation between in vitro and in vivo results [J]. Int J Cancer,1996, 66(3):374.
  • 4Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor-alpha- phase Ⅰ and phase Ⅱ clinical trial [J]. Pol Merkuriusz Lek,1997,2(12):396.
  • 5Libutt: SK; Barlett DJ, Fraker DL et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies[J]. J Am Coll Surg. 2000,191(5):519.
  • 6Tomita AM, Fuchino Y, Otsukak, et al. Clinical effects of exogenous/endogenous TNF therepy on metastatic lesions of 34 colorectal cancer patients[J]. Anticancer Res, 1998, 18(SD):3937.
  • 7Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res, 1998, 18 (5D):3937-3939.
  • 8Xi T, Shi X, Guo D, et al. Biological activities of human tumor necrosis factor-alpha and its novel mutants. Biochem Mol Biol Int, 1996, 38 (4): 855-862.
  • 9Kircheis R, Ostermann E, Wolschek MF, et al. Tumortargeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther, 2002, 9 (8): 673-680.
  • 10Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 65 (1-2): 55-63.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部